Eyecare company Clearside Biomedical announced that patients treated with its injectable eye disease candidate demonstrated improved vision, as it tries to become the first to commercialize suprachoroidal delivery.
The success of Biogen Idec's closely watched antibody targeting beta amyloid proteins in Alzheimer's disease is again bringing some excitement to a category that has defeated earlier enthusiasm as drugs have failed in trials.
Dermatology outfit Sebacia is touting promising results for its acne-treating technology from two recent clinical studies that show its gold microparticles significantly reduced acne in patients.
As the med tech industry turns its attention to devices that can treat and prevent bedsores, a team of GE researchers is developing an innovative handheld probe that can prevent the sores, or pressure ulcers, from forming during hospital stays.
The University of Arizona has launched a study designed to explore whether dogs promote the growth of probiotics--the so-called good bacteria--in their owners.
Sanofi is shipping more than 200 researchers to German outsourcing firm Evotec as it finally gets out of a French R&D site whose fate led to a squabble with the local government, reaching a compromise the company believes will leave all sides appeased.
Cloud Pharmaceuticals has taken the next step in its push to create a pipeline of drugs discovered using a computer-based design process, hooking up with the University of Florida to transition its computer-discovered drugs into traditional preclinical research.
Sirtex Medical's clinical trial of its microspheres for targeted delivery of radioactive particles did not live up to expectations. Investors dumped the Australian company's stock in a hurry beginning March 13. It began the following week at $15, or a stunning 60% lower than before the bad news was delivered.
Juno Therapeutics quickly built a reputation as one of the hottest biotechs in the world, raising hundreds of millions of dollars inside a year and capping it with a go-go IPO for its cancer drug pipeline that helped inspire a surge for the sector. And now that the newly public biotech has filed its first 10-K, Juno can feel the backlash as it outlines just how fast it can spend that huge cache of cash, missing a consensus estimate on projected losses by a market mile.
Slowly but surely, Google's star-driven biotech Calico is laying the foundation for what promises to be a major biotech focused on some of the biggest diseases that limit longevity. There's a Big Pharma partnership with AbbVie, a development deal down in Texas and now it's time to team up with top scientists. Earlier in the week Harvard and MIT's renowned Broad Institute signed on to work with Calico on pushing new therapies into the clinic.